Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.48 |
| ▸ | L3MBTL3 | Q96JM7 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13806535 | 0.81 | ALDH1A1 (0.50) | KDM1AALDH1A1CYP3A4MAPTCYP2C9 | |
| SCHEMBL1238942 | 0.81 | NPC1 (0.50) | KMT2ASMN1; SMN2ALDH1A1NPC1TDP1 | |
| SCHEMBL1240830 | 0.81 | NPC1 (0.68) | KMT2ATSHRSMN1; SMN2L3MBTL1ALDH1A1 | |
| SCHEMBL23240345 | 0.79 | SMN1; SMN2 (0.58) | KMT2ATSHRSMN1; SMN2HPGDL3MBTL1 | |
| SCHEMBL1241723 | 0.78 | MEN1 (0.51) | KMT2ASMN1; SMN2L3MBTL3L3MBTL1ALDH1A1 | |
| SCHEMBL28043029 | 0.78 | NPC1 (0.48) | KMT2ASMN1; SMN2ALDH1A1NPC1TDP1 | |
| SCHEMBL1241136 | 0.77 | NPC1 (0.50) | KMT2ASMN1; SMN2ALDH1A1NPC1TDP1 | |
| SCHEMBL2151226 | 0.77 | MEN1 (0.48) | KMT2ASMN1; SMN2ALDH1A1NPC1TDP1 | |
| Hydrochloric Acid SCHEMBL9237496 | 0.77 | GABRD (0.43) | — | |
| SCHEMBL15576254 | 0.76 | MEN1 (0.50) | KMT2ASMN1; SMN2HPGDALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586614-B2 | Urea glucokinase activators | NOVO NORDISK A/S (DK) | 2013-11-19 | — | — | US | disclosed |
| US-20110077234-A1 | Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2011-03-31 | — | — | US | disclosed |
| US-7884210-B2 | {2-[3-(2-Cyclohex-1-enyl-ethyl)-3-(trans-4-methyl-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid; for treatment of type 2 diabetes | NOVO NORDISK A/S (DK) | 2011-02-08 | — | — | US | disclosed |
| US-20090105482-A1 | Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| EP-1904467-A1 | UREA GLUCOKINASE ACTIVATORS | Novo Nordisk A/S (DK) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007006814-A1 | UREA GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105482-A1 | Urea Glucokinase Activators | GCK, GCKR, HK2 | KDM1A 1184/4885KMT2A 1200/4885TSHR 3898/4885 |
| US-20110077234-A1 | Urea Glucokinase Activators | GCK, GCKR, HK2 | KDM1A 1184/4885KMT2A 1200/4885TSHR 3898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.